Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. Jain RK, Swami U, Bilen MA, Gebrael G, et al. Eur Urol Oncol 2025;8:952-960.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jain RK, Swami U, Bilen MA, Gebrael G, et al. Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. Eur Urol Oncol 2025;8:952-960.
PMID: 40307092